Meglumine lodipamide (Cholografin®) Hepatotoxicity

  1. L. R. SUTHERLAND, M.D.;
  2. L. A. EDWARDS, M.D., F.R.C.P.(C);
  3. A. MEDLINE, M.D., F.R.C.P.(C);
  4. R. W. WILKINSON, M.D., F.R.C.S.(C); and
  5. J. J. CONNON, M.D., M.R.C.P.(Lond), F.R.C.P.(C)
  1. Toronto
    , Canada

    Abstract

    Two cases of meglumine iodipamide (Cholografin®) hepatotoxicity were confirmed by liver biopsy. The hepatic lesion was centrilobular in location and resolved within a short period of time. Nausea and vomiting commonly reported after intravenous cholangiography may be clinical manifestations of this entity.

    Article and Author Information

    • ▸From the Departments of Medicine, Pathology, and Surgery, Toronto Western Hospital; and the Department of Medicine, Humber Memorial Hospital; Toronto, Canada.

    • ▸Requests for reprints should be addressed to J. J. Connon, M.D.; Department of Medicine (Gastroenterology), Toronto Western Hospital, 399 Bathurst St.; Toronto, ON M5T 2S8, Canada.

      • Received July 21, 1976.
      • Accepted January 12, 1977.
    « Previous | Next Article »Table of Contents